137 completed, 41 unknown, 28 recruiting, 27 terminated. 105 Phase 2, 53 Phase 1, 26 Phase 3, 19 Not applicable, 8 Phase 4.
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 22 | 2026-11-01 | 2026-10-29 |
| A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region Chronic Myeloid Leukemia | Not yet recruiting | Novartis Pharmaceuticals | 80 | 2026-10-29 | 2026-10-27 | |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines Chronic Myeloid Leukemia, Chronic Myeloid Leukemia - Chronic Phase | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 98 | 2026-09-01 | 2026-06-11 | |
| Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Ropeginterferon alfa-2b (P1101) - Chronic Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-07-13 | 2026-10-13 |
| Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients Tyrosine kinase Inhibitors (Imatinib & Nilotinib) - Chronic Myeloid Leukemia | Not yet recruiting | Assiut University | 75 | 2026-05-01 | 2026-02-18 | |
| Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase Olverembatinib 20mg - Chronic Myeloid Leukemia | Enrolling by invitation | Qian Jiang | 100 | 2025-12-16 | 2026-02-03 | |
| Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib olverembatinib - Chronic Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2025-10-13 | 2026-10-01 |
| Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Not yet recruiting | Assiut University | 66 | 2025-10-01 | 2025-08-28 | |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias CBX-250 - High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Recruiting | Crossbow Therapeutics, Inc. | 72 | 2025-07-16 | 2026-03-16 |
| TGRX-678 Pharmacokinetic Mass Balance [14C]TGRX-678 - Chronic Myeloid Leukemia | Phase 1 | Completed | Shenzhen TargetRx Co., Ltd. | 6 | 2025-07-07 | 2025-09-04 |
| PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Asciminib, Nilotinib - CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 160 | 2025-06-26 | 2025-07-08 |
| Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor Ruxolitinib, Abatacept (Orencia) - Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 60 | 2025-05-10 | 2025-11-20 |
| TGRX-678 Phase I Oral Pharmacokinetic Study TGRX-678 - Chronic Myeloid Leukemia | Phase 1 | Completed | Shenzhen TargetRx Co., Ltd. | 76 | 2024-11-24 | 2025-05-16 |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients TGRX-678 - Chronic Myeloid Leukemia, Accelerated Phase CML | Phase 2 | Recruiting | Shenzhen TargetRx Co., Ltd. | 40 | 2024-07-15 | 2025-02-21 |
| The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP Ponatinib, Azacitidine, Venetoclax - Chronic Myeloid Leukemia | Recruiting | Peking University People's Hospital | 30 | 2024-07-01 | 2025-06-03 | |
| Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen Sorafenib - Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 88 | 2024-05-22 | 2024-08-01 |
Showing 20 of 270. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (270) · Leukemia, Myeloid, Acute (69) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (58) · Myelodysplastic Syndromes (57) · Lymphoma, Non-Hodgkin (29) · Leukemia (26) · Leukemia, Lymphocytic, Chronic, B-Cell (19) · Multiple Myeloma (19) · Hodgkin Disease (18) · Myeloproliferative Disorders (17) · Hematologic Neoplasms (15) · Leukemia, Myeloid, Chronic-Phase (15) · Primary Myelofibrosis (13) · Graft vs Host Disease (10) · Anemia, Refractory, with Excess of Blasts (9)
Chronic Disease (270) · Disease Attributes (270) · Hemic and Lymphatic Diseases (270) · Pathologic Processes (270) · Pathological Conditions, Signs and Symptoms (270) · Bone Marrow Diseases (267) · Neoplasms by Histologic Type (267) · Leukemia, Myeloid (265) · Neoplasms (264) · Hematologic Diseases (263) · Myeloproliferative Disorders (253) · Leukemia (244) · Immune System Diseases (75) · Immunoproliferative Disorders (69) · Lymphatic Diseases (68)
Imatinib Mesylate (44) · nilotinib (36) · Dasatinib (24) · fludarabine (12) · Cyclophosphamide (11) · fludarabine phosphate (10) · bosutinib (9) · ponatinib (9) · Busulfan (8) · Mycophenolic Acid (8) · asciminib (8) · Tacrolimus (7) · Whole-Body Irradiation (7) · Filgrastim (5) · Granulocyte Colony-Stimulating Factor (5)
Novartis Pharmaceuticals (23) · Gruppo Italiano Malattie EMatologiche dell'Adulto (15) · M.D. Anderson Cancer Center (13) · Bristol-Myers Squibb (10) · Poitiers University Hospital (8) · Assiut University (5) · St. Jude Children's Research Hospital (5) · St. Petersburg State Pavlov Medical University (4) · University of Bologna (4) · University of Michigan Rogel Cancer Center (4) · Baylor College of Medicine (3) · Nanfang Hospital, Southern Medical University (3) · Pfizer (3) · Seoul St. Mary's Hospital (3) · Shenzhen TargetRx Co., Ltd. (3)
United States (105) · France (49) · Italy (47) · Germany (39) · Canada (26) · China (25) · South Korea (25) · Spain (23) · United Kingdom (23) · Netherlands (20) · Australia (17) · Belgium (17) · Russia (17) · Singapore (15) · Israel (14)
Jorge Cortes, MD (6) · Fabio Efficace, PhD (4) · Michele Baccarani, MD (4) · Arnon Nagler, MD (3) · Fausto Castagnetti (3) · Gregory Hale, M.D. (3) · Alessandra Iurlo, MD (2) · Anna Turkina, Professor (2) · Dong-Wook Kim, MD, PhD (2) · Elisabetta Abruzzese, MD (2) · Fadi Haddad, MD (2)
PMID 22825216, PMID 35235189, PMID 23116602, PMID 24919837, PMID 25361995, PMID 11756187, PMID 16990776, PMID 18838477, PMID 19264678, PMID 19695406, PMID 19797518, PMID 19822896, PMID 20145273, PMID 20385986, PMID 20946966, PMID 20965785, PMID 21145590, PMID 21175313, PMID 21237680, PMID 21447834, PMID 21450900, PMID 21478667, PMID 21540460, PMID 21670449, PMID 21750313, PMID 21865346, PMID 22036634, PMID 22047558, PMID 22371878, PMID 22511495, PMID 22692507, PMID 22896000, PMID 22949154, PMID 22987089, PMID 22987312, PMID 23065508, PMID 23328954, PMID 23440689, PMID 23468307, PMID 23524640, PMID 23678005, PMID 23704092, PMID 23971909, PMID 24060561, PMID 24105694, PMID 24123600, PMID 24166905, PMID 24180494, PMID 24323036, PMID 24345751
2015 (3), 2005 (2), 2008 (2), 2009 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), P01CA015396 (1), P01CA049605 (1), UG1CA189823 (1)